Spain's demographic profile is one of the most important drivers of its dry AMD market. The country has one of the highest life expectancies in Europe, and approximately 19% of the population is aged 65 or older. AMD prevalence rises sharply with age, and as Spain's population continues to age, the number of people affected by dry AMD is increasing. This demographic trend creates sustained demand for diagnostics, monitoring, and treatment.

The Spain Dry Age Related Macular Degeneration Market reflects this demographic reality. Older adults represent the core patient population, and their numbers are growing. Regional patterns are notable: rural and aging regions tend to have higher prevalence, while urban centres often have better access to specialist care. This creates challenges for equitable access, but also opportunities for teleophthalmology and remote monitoring.

Awareness is also increasing, supported by ophthalmology societies, patient organisations, and public health campaigns. Primary care physicians are becoming more attuned to AMD risk factors and referral pathways. Meanwhile, emerging therapies are expected to expand treatment options, particularly for patients with geographic atrophy, a severe form of dry AMD. As Spain's population continues to age and new therapies arrive, the Spain Dry AMD Market is expected to grow steadily, driven by long-term demographic forces and clinical innovation.

People Also Ask

• Why is dry AMD more common in Spain?
  Spain has one of Europe's oldest populations, and AMD prevalence rises significantly with age.

• How are regional differences addressed in Spain?
  Teleophthalmology, remote monitoring, and regional investment in ophthalmology capacity are helping address access disparities.

Tags: #AgingPopulation #DryAMD #SpainHealthcare #MacularDegeneration #TeleOphthalmology #EyeCare